Table 5.
Comparison of adverse events in adenoviral vaccines vs. others for COVID-19 in Africa.
| Bleeding | n = 918 | AEFV | % | p-Value |
|---|---|---|---|---|
| Adenovector | 733 | 37 | 5 | 0.33 |
| mRNA | 98 | 5 | 5.1 | |
| Inactivated vaccine | 57 | 6 | 10.5 | |
| Live attenuated | 2 | 0 | 0 | |
| Others | 28 | 3 | 10.7 | |
| Seizure | ||||
| Adenovector | 728 | 31 | 4.3 | 0.10 |
| mRNA | 102 | 3 | 2.9 | |
| Inactivated vaccine | 60 | 4 | 6.7 | |
| Live attenuated | 2 | 0 | 0 | |
| Others | 28 | 4 | 14.3 | |
| Breathing difficulty | ||||
| Adenovector | 750 | 19 | 2.5 | 0.90 |
| mRNA | 100 | 3 | 3 | |
| Inactivated vaccine | 61 | 2 | 3.3 | |
| Live attenuated | 2 | 0 | 0 | |
| Others | 30 | 5 | 16.7 | |
| Hearing/Vision | ||||
| Adenovector | 757 | 11 | 1.5 | 0.09 |
| mRNA | 101 | 3 | 2.9 | |
| Inactivated vaccine | 60 | 3 | 5 | |
| Live attenuated | 2 | 0 | 0 | |
| Others | 28 | 4 | 14.3 | |
| Severe allergic reaction | ||||
| Adenovector | 752 | 16 | 2.1 | 0.35 |
| mRNA | 102 | 3 | 2.9 | |
| Inactivated vaccine | 60 | 3 | 5 | |
| Live attenuated | 2 | 0 | 0 | |
| Others | 28 | 4 | 14.3 | |